Literature DB >> 3948183

Estrogen and progesterone receptors in breast cancer among women of different racial groups.

R J Pegoraro, V Karnan, D Nirmul, S M Joubert.   

Abstract

No differences in steroid hormone receptor status were detected in premenopausal breast cancer patients of different races. In postmenopausal women, 65% of Whites were found to have tumors positive for cytoplasmic estrogen receptors (CER) compared with 58, 52, and 41% in women of mixed race, Blacks, and Asians, respectively. The proportions of tumors which contained a full complement of receptors (CER, nuclear estrogen receptors, and cytoplasmic progesterone receptors) were similar in Blacks, Whites, and Asians in each menopausal group. In postmenopausal patients, significantly fewer White women had tumors devoid of all receptors, while having a higher incidence of tumors with an abnormal or defective receptor distribution. Neither the stage of the disease nor the degree of nodal involvement appeared to affect receptor status in any population group, but very large tumors had fewer receptors. White patients with large neoplasms had a significantly higher incidence of CER than Blacks or Asians. Similar observations were made for White patients presenting with Stage III disease, whose tumors were greater of histological Grade I tumors were positive for CER, compared with Grade III neoplasms. Indications are that receptor status is inherent to the natural history of the disease and is not influenced by clinical features.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948183

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.

Authors:  Christina A Clarke; Theresa H M Keegan; Juan Yang; David J Press; Allison W Kurian; Anish H Patel; James V Lacey
Journal:  J Natl Cancer Inst       Date:  2012-07-05       Impact factor: 13.506

2.  Temporal trends in the black/white breast cancer case ratio for estrogen receptor status: disparities are historically contingent, not innate.

Authors:  Nancy Krieger; Jarvis T Chen; Pamela D Waterman
Journal:  Cancer Causes Control       Date:  2010-12-25       Impact factor: 2.506

3.  Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Authors:  Maher A Sughayer; Maha M Al-Khawaja; Suleiman Massarweh; Mahmoud Al-Masri
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

4.  A comprehensive information database (CID) of breast cancer patients in China.

Authors:  Shuai Li; Li Fu
Journal:  Front Med       Date:  2012-05-08       Impact factor: 4.592

5.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

Review 6.  Breast cancer in African American women: epidemiology and tumor biology.

Authors:  B J Trock
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal.

Authors:  Subhojit Dey
Journal:  World J Clin Oncol       Date:  2014-08-10

8.  Pathological characteristics of BRCA-associated breast cancers in Hispanics.

Authors:  Veronica I Lagos-Jaramillo; Michael F Press; Charité N Ricker; Louis Dubeau; Phuong L Mai; Jeffrey N Weitzel
Journal:  Breast Cancer Res Treat       Date:  2011-05-21       Impact factor: 4.872

9.  Breast cancer: a neglected disease for the majority of affected women worldwide.

Authors:  Ophira M Ginsburg; Richard R Love
Journal:  Breast J       Date:  2011-03-16       Impact factor: 2.431

10.  Factors that influence the incidence of breast cancer in Arica, Chile (Review).

Authors:  Gloria M Calaf; Fresia Caba; Jorge Farias; Francisco Rothhammer
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.